BMBrit Mollenhauer

Brit Mollenhauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brit Mollenhauer has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

    by Franziska Hopfner, Stefanie H. Müller, Dagmar Steppat, Joanna Miller, Nele Schmidt, Klaus-Peter Wandinger, Frank Leypoldt, Daniela Berg, Andre Franke, Wolfgang Lieb, et al.

    IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment (n = 296) and controls (n = 295) free of neuropsychiatric disease. Detailed phenotyping and large numbers allowed statistically meaningful correlation of antibody status with diagnostic subgroups as well as quantitative indicators of disease severity and cognitive impairment. NMDA antibodies were analysed in the serum of patients and controls using well established validated assays. We used anti-NMDA antibody positivity as the main independent variable and correlated it with disease status and phenotypic characteristics. The frequency of NMDA IgA/IgM antibodies was lower in Parkinson patients (13%) than in controls (22%) and higher than in previous studies in both groups. NMDA IgA/IgM antibodies were neither significantly associated with diagnostic subclasses of Parkinson disease according to cognitive impairment, nor with quantitative indicators of disease severity and cognitive impairment. A positive NMDA antibody status was positively correlated with age in controls but not in Parkinson patients. It is unlikely albeit not impossible that NMDA antibodies play a significant role in the pathogenesis or progression of Parkinson disease e.g. to Parkinson disease with dementia, while NMDA IgG antibodies define a separate disease of its own.


  • What can biomarkers tell us about cognition in Parkinson's disease?

    by Brit Mollenhauer, Lynn Rochester, Alice Chen‐Plotkin, David Brooks

    Cognitive decline is common in Parkinson's disease (PD), even in the early motor stage, and this non‐motor feature impacts quality of life and prognosis tremendously. In this article, we discuss marker candidates for cognitive decline in PD from different angles, including functional and structural imaging techniques, biological fluid markers in cerebrospinal fluid, and blood genetic predictors, as well as gait as a surrogate marker of cognitive decline. Specifically, imaging‐based markers of cognitive impairment in PD include cortical atrophy, reduced cortical metabolism, loss of cortical cholinergic and frontal dopaminergic function, as well as an increased cortical amyloid load. Reduced β‐amyloid(1‐42) in cerebrospinal fluid and lower plasma levels of epidermal growth factor are predictors for cognitive decline in PD. In addition, genetic variation in the apolipoprotein E (APOE), catechol‐O‐methyltransferase (COMT), microtubule‐associated protein tau (MAPT), and glucocerebrosidase (GBA) genes may confer risk for cognitive impairment in PD; and gait disturbance may also indicate an increased risk for dementia. Other marker candidates have been proposed and are discussed. All of the current studies are hampered by gaps in our knowledge about the molecular causes of cognitive decline, which will have to be considered in future biomarker studies. © 2014 International Parkinson and Movement Disorder Society


  • Früherkennung der Parkinson-Krankheit

    by B. Mollenhauer, F. Sixel-Döring, A. Storch, C. Schneider, R. Hilker, E. Kalbe


  • Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

    by Brit Mollenhauer, Ellen Trautmann, Peggy Taylor, Paul Manninger, Friederike Sixel-Döring, Jens Ebentheuer, Claudia Trenkwalder, Michael G. Schlossmacher


  • Plasma Amyloid-BetaPeptides in Acute Cerebral Ischemia: A Pilot Study

    by Mirko Bibl, Volker Welge, Holger Schmidt, Hermann Esselmann, Brit Mollenhauer, Piotr Lewczuk, Markus Otto, Johannes Kornhuber, Jens Wiltfang

    Blood-based tests for a rapid and valid diagnosis as well as outcome prognosis of acute stroke are desirable. Recently, plasma Aβ40 was suggested as an independent cerebrovascular risk factor candidate. We investigated eight plasma samples of patients with clinical signs of acute cerebral ischemia for derangements of plasma amyloid-beta (Aβ) peptide patterns as compared to 13 patients with other neuropsychiatric diseases. For the analysis of plasma, we used immunoprecipitation followed by the quantitative Aβ-SDS-PAGE/immunoblot. The major outcome was a striking decrease of Aβ1-40 in plasma paralleled by an increase in the ratio of Aβ1-38/Aβ1-40 in two patients with acute stroke. Interestingly, these patients had an onset of symptoms within only 2-4 hr before venous puncture and there was a strong correlation of Aβ1-38/Aβ1-40 levels with the time span between onset of symptoms and venous puncture. From these results, we suggest the ratio of plasma Aβ1-38/Aβ1-40 as a possible biomarker for the early diagnosis of acute stroke.


  • Open Access

    α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system

    by Brit Mollenhauer, Ellen Trautmann, Birgit Otte, Juliana Ng, Annette Spreer, Peter Lange, Friederike Sixel-Döring, Mansoureh Hakimi, Jean-Paul VonSattel, Robert Nussbaum, et al.

    The source of Parkinson disease-linked α-synuclein (aSyn) in human cerebrospinal fluid (CSF) remains unknown. We decided to measure the concentration of aSyn and its gradient in human CSF specimens and compared it with serum to explore its origin. We correlated aSyn concentrations in CSF versus serum (QaSyn) to the albumin quotient (Qalbumin) to evaluate its relation to blood–CSF barrier function. We also compared aSyn with several other CSF constituents of either central or peripheral sources (or both) including albumin, neuron-specific enolase, β-trace protein and total protein content. Finally, we examined whether aSyn is present within the structures of the choroid plexus (CP). We observed that QaSyn did not rise or fall with Qalbumin values, a relative measure of blood–CSF barrier integrity. In our CSF gradient analyses, aSyn levels decreased slightly from rostral to caudal fractions, in parallel to the recorded changes for neuron-specific enolase; the opposite trend was recorded for total protein, albumin and β-trace protein. The latter showed higher concentrations in caudal CSF fractions due to the diffusion-mediated transfer of proteins from blood and leptomeninges into CSF in the lower regions of the spine. In postmortem sections of human brain, we detected highly variable aSyn reactivity within the epithelial cell layer of CP in patients diagnosed with a range of neurological diseases; however, in sections of mice that express only human SNCA alleles (and in those without any Snca gene expression), we detected no aSyn signal in the epithelial cells of the CP. We conclude from these complementary results that despite its higher levels in peripheral blood products, neurons of the brain and spinal cord represent the principal source of aSyn in human CSF.


  • Open Access

    Erratum to: Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease

    by Brit Mollenhauer, Hermann Esselmann, Sigrun Roeber, Walter J. Schulz-Schaeffer, Claudia Trenkwalder, Mirko Bibl, Petra Steinacker, Hans A. Kretzschmar, Jens Wiltfang, Markus Otto


  • CSF Amyloid-β Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease

    by Brit Mollenhauer, Herrmann Esselmann, Claudia Trenkwalder, Walter Schulz-Schaeffer, Hans Kretzschmar, Markus Otto, Jens Wiltfang, Mirko Bibl

    Appropriate treatment of dementia requires biomarkers that provide an exact and differential diagnosis. We recently presented differentially expressed amyloid-β (Aβ) peptide patterns in cerebrospinal fluid (CSF) as biomarker candidates for neurochemi


  • α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

    by Brit Mollenhauer, Joseph J Locascio, Walter Schulz-Schaeffer, Friederike Sixel-Döring, Claudia Trenkwalder, Michael G Schlossmacher